- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
ASCO Annual Meeting | Conferences
Efficacy of Neoadjuvant/Adjuvant Pembrolizumab in TNBC
June 16, 2022
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
MOMENTUM Aims to Complete Development of Momelotinib for Myelofibrosis Treatment
June 16, 2022
Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.
Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma
June 08, 2022
The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.
Positive Responses Shown With Rivoceranib in Patients With Adenoid Cystic Carcinoma
June 08, 2022
Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer
June 08, 2022
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors
June 07, 2022
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.
Selinexor Improves PFS in Patients with Endometrial Cancer and in Those with p53 Wild-type Status
June 07, 2022
Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.
Reduced Risk of Metastatic Progression With Darolutamide in Patients With nmCRPC
June 07, 2022
Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
Intensified Chemotherapy Does Not Improve Efficacy With Panitumumab in mCRC
June 07, 2022
FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.
LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers
June 07, 2022
According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.